A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

NCT01317901 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Small Lymphocytic Lymphoma Recurrent

Interventions

DRUG: TRU-016
DRUG: Bendamustine
DRUG: Rituximab

Sponsor

Aptevo Therapeutics